Prostate cancer: new immunotherapy could prevent resistance to hormone therapy
A new form of immunotherapy using innovative nanoparticles can delay resistance to hormone therapy and…
Author ONA Editor
ONA Editor
The ONA Editor curates oncology news, views and reviews from Australia and around the world for our readers. In aggregated content, original sources will be acknowledged in the article footer.
FDA approves new therapy for glioma patients for first time in decades
Vorasidenib has been approved by the U.S. Food and Drug Administration (FDA) for patients with…
Meteorin-like protein drains energy from T cells
A protein called Meteorin-like (METRNL) in the tumour microenvironment saps energy from T cells, thereby…
Study suggests an MRI may help doctors predict more aggressive prostate cancer in patients
Corewell Health research suggests an MRI scan can help predict whether patients with intermediate-risk prostate…
Classifying glioblastoma’s molecular profiles for precision medicine
A transformative study has provided a profound understanding of glioblastoma’s molecular subtypes, revealing the nuances…
Tpex cells: the game-changer in targeted tumour immunotherapy
Progenitor exhausted CD8+ T (Tpex) cells have emerged as a pivotal component in tumour immunotherapy due…
Scientists identify genes linked to relapse in the most common form of childhood leukaemia
Scientists from St. Jude Children’s Research Hospital, Seattle Children’s and the Children’s Oncology Group (COG),…
Decoding calcifications in breast cancer: Towards personalised medicine
A pivotal study uncovers the molecular signatures of mammographic calcifications in hormone receptor-positive, HER2-negative breast…
Immune landscape and response to oncolytic virus-based immunotherapy
Oncolytic virus (OV)-based immunotherapy has emerged as a promising strategy for cancer treatment, offering a…
Study reveals diet as main risk factor for colon cancer in younger adults
A new Cleveland Clinic (USA) study has identified diet-derived molecules called metabolites as main drivers…